Trials / No Longer Available
No Longer AvailableNCT04221412
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Sciences Ireland UC · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus \[RSV\] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-53718678 | JNJ-53718678 will be administered as directed by treating physician. |
Timeline
- First posted
- 2020-01-09
- Last updated
- 2022-08-29
Source: ClinicalTrials.gov record NCT04221412. Inclusion in this directory is not an endorsement.